Physician profile
Scott A Kendrick
NPI 1104042365
$2,101.21
in general payments reported to CMS, 2019-2025
30 companies · $133 in 2025
The $133 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $429 · 2020: $323 · 2021: $302 · 2022: $205 · 2023: $201 · 2024: $508 · 2025: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $525 · Travel and Lodging: $299 · Education: $16.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $525.23 |
| Travel and Lodging | $299.16 |
| Education | $16.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spinal Simplicity, LLC | $299.16 | 2024 | Ha Minuteman G3-R |
| Astrazeneca Pharmaceuticals LP | $219.58 | 2020-2023 | Farxiga |
| Amgen INC. | $197.40 | 2019-2025 | Tavneos |
| Nxstage Medical, INC. | $135.18 | 2023 | Nxstage System One, Liberty Select Cycler |
| Mml US, INC. | $126.79 | 2024 | Reactiv8 |
| Otsuka America Pharmaceutical, INC. | $126.05 | 2019-2022 | |
| Opko Pharmaceuticals, LLC | $87.36 | 2019-2023 | Rayaldee |
| Glaxosmithkline, LLC. | $86.43 | 2021-2024 | Benlysta |
| Alexion Pharmaceuticals, INC. | $74.11 | 2020-2024 | Ultomiris |
| Fresenius USA Marketing, INC. | $59.66 | 2019-2021 | |
| Vifor Pharma, INC. | $59.41 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $59.23 | 2020-2021 | |
| Nevro Corp. | $57.94 | 2019 | |
| Akebia Therapeutics INC | $57.29 | 2019-2020 | |
| Boston Scientific Corporation | $42.26 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $39.61 | 2019-2022 | |
| Travere Therapeutics, INC. | $39.05 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $37.66 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $35.07 | 2020-2025 | Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $33.35 | 2022 | |
| Novartis Pharmaceuticals Corporation | $32.50 | 2025 | |
| Assertio Therapeutics, INC. | $29.13 | 2019 | |
| Biomerieux INC | $28.61 | 2019 | |
| Depuy Synthes Sales INC. | $28.38 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.47 | 2020-2021 | |
| Ultragenyx Pharmaceutical INC. | $22.80 | 2020 | |
| Calliditas Therapeutics US INC. | $17.91 | 2022 | |
| Scpharmaceuticals INC. | $15.98 | 2025 | |
| Lilly USA, LLC | $13.64 | 2024 | Jardiance |
| Novo Nordisk INC | $13.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Kendrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.